Using an in vitro double labeling technique with two different levels of @entity665 , the duration of the phase of DNA synthesis (S) and the @entity894 ( @entity894 ) were measured in the colorectal mucosa of three groups of @entity1 : @entity1 with @entity14 ( @entity652 and/or @entity420 ), @entity1 with @entity29 , and a control group of @entity1 without gastrointestinal pathology. In those @entity1 with @entity14 , samples were obtained from both the neoplastic mucosa and from the normal appearing mucosa at various distances from the lesions. One-way analyses of variance were used to test the equality of mean S-phase duration and @entity894 in the various types of tissues. S-phase duration was significantly longer in the @entity5 than in the unaffected mucosa of @entity1 with @entity420 (18.65 hours +/- 2.3 versus 10.13 hours +/- 1.26 P less than 0.0001). However, S-phase duration was significantly longer in the unaffected mucosa of @entity5 @entity1 than in the mucosa of @entity1 without gastrointestinal pathology (10.58 hours +/- 1.84 versus 7.91 hours +/- 0.46, P = 0.013). Similarly, @entity894 was significantly higher in the unaffected mucosa of @entity1 with @entity652 and @entity420 than in the mucosa of @entity1 without gastrointestinal pathology (19.1% +/- 3.0 versus 9.5% +/- 2.2, P less than 0.0001). There was a highly significant trend to a progressive increase of @entity894 from flat histologically normal appearing mucosas to inflammatory mucosas, @entity652 , and @entity420 (P less than 0.0001). These results suggest that increased S-phase duration is specifically related to @entity5 . In mucosa without histologic sign of @entity5 , an increased S-phase duration would indicate that the malignant process has started. An increased @entity894 would appear to relate to the selective advantage that rapidly proliferating cells hold over less proliferating ones.

Cell kinetic indicators of premalignant stages of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity894 :: ('MESH:C566784', 'Disease') :: ['labeling index', 'LI'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'malignancy'] @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease'] @entity665 :: ('CHEBI:53526', 'Chemical') :: ['3H-thymidine'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal neoplasms'] @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas', 'adenoma'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas', 'adenocarcinoma']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
